Clinical trials: Hepatic Cirrhosis
Cirrhosis
Albumin Administration in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis
Spontaneous bacterial peritonitis (SBP) present in cirrhotic patients induces severe circulatory dysfunction, which results in renal failure in up to 30% of the patients.
- Trial name
- Infecir (NCT00124228)
- Testing
- Human Albumin
- Where
- Spain
- Volunteers
- 110 people
- Sponsor
- Hospital Clinic of Barcelona
Cirrhosis
Propofol Versus Midazolam for Upper Endoscopy in Cirrhotic Patients
Upper GI endoscopy is often performed in patients with chronic liver disease to screen for esophageal and gastric varices. The purpose of this study is to compare propofol to midazolam for sedation in patients with chronic liver…
- Trial name
- NCT01141036
- Testing
- propofol, Midazolam
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Ziv Hospital
Liver Cancer
Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well temsirolimus works in treating patients with advanced liver…
- Trial name
- NCT01079767
- Testing
- temsirolimus
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Acute Kidney Injury, Cirrhosis
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital.
- Conditions
- Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
- Trial name
- DROP-AKI (NCT06937307)
- Testing
- Droxidopa capsules
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Giuseppe Cullaro, MD
Hepatitis C, Cirrhosis
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
The investigators will treat 50 patients with cirrhosis due to hepatitis C genotype 1, with sofosbuvir 400 mg daily, ledipasvir 90 mg daily and weight-based ribavirin (1000 mg/d if <75 kg, 1200 mg/d if >75 kg, divided in two…
- Trial name
- SL50 (NCT02705534)
- Testing
- Sofosbuvir, Ledipasvir, Ribavirin
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Tehran University of Medical Sciences
Primary Biliary Cholangitis
Monitoring the Response of Combination Ursodiol and Seladelpar Treatment
This study aims to provide comprehensive insights into the therapeutic effects of combination treatment with ursodiol and seladelpar in PBC patients by assessing biochemical responses using biomarkers such as ALP and total…
- Trial name
- NCT07122206
- Testing
- Blood Draws
- Volunteers
- 100 people
- Sponsor
- Methodist Health System
Benign Liver Tumor, Malignant Tumor Liver
Liver Resection Modeling
Despite the medical and surgical progress of the last two decades, the selection of candidates for liver surgery remains based on old principles and insufficiently sensitive to fine-tune the gesture to patient-specific…
- Conditions
- Benign Liver Tumor, Malignant Tumor Liver, Cirrhosis
- Trial name
- LRM (NCT04023136)
- Testing
- partial hepatectomy by laparotomy on healthy or pathologic parenchyma.
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatic Fibrosis
QTc Assessment in a Single-Dose Study of Hydronidone Capsules
This study was designed with three dose cohorts (A1-A3): a 90 mg cohort, a 270 mg cohort, and a 540 mg cohort. Each cohort enrolled 16 healthy Chinese participants, with 12 receiving the investigational product Hydronidone…
- Trial name
- NCT07263152
- Testing
- Hydronidone
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic
To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients
A phase II study to evaluate the efficacy and safety in TG-2349 combination with DAG181 (± Ribavirin) in treatment naïve subjects with chronic hepatic C virus genotype I infection.
- Conditions
- Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis, Treatment naïve
- Trial name
- NCT03593447
- Testing
- non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin, non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin, non-cirrhotic subjects. low TG-2349+ low DAG181
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Non-alcoholic Steatohepatitis, Liver Diseases
Reducing Non-Alcoholic Steatohepatitis
The goal of this clinical trial is to learn if empagliflozin works to treat non-alcoholic steatohepatitis in adults. The objectives are: Primary Objective To evaluate the change in histological grading and staging of NASH in…
- Conditions
- Non-alcoholic Steatohepatitis, Liver Diseases, Diabetes Mellitus, Type 2, Fibrosis, Liver
- Trial name
- RedNASH (NCT06519448)
- Testing
- Empagliflozin 10 miligrams (mg)
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Military University Hospital, Prague
Liver Fibrosis, Hepatitis C Virus
Magnetic Resonance Elastography for Assessment of Liver Fibrosis (MK-0000-132)(COMPLETED)
This study will assess the repeatability of Magnetic Resonance Elastography (MRE) in both healthy volunteers and Hepatitis C Virus (HCV)-infected patients with fibrosis and lay the groundwork for the validation of MRE as an…
- Trial name
- NCT00896233
- Testing
- MRE
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Primary Biliary Cholangitis, Primary Biliary Cirrhosis
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
The purpose of this open-label study is to evaluate the safety and tolerability of HDT1801 (BUDCA) over 12 weeks in adult subjects with PBC who have an inadequate response to standard therapy.
- Conditions
- Primary Biliary Cholangitis, Primary Biliary Cirrhosis, Cholangitis, Cholestasis
- Trial name
- PRONTO-PBC (NCT04604652)
- Testing
- HTD1801 (BUDCA)
- Where
- 12 sites in United States
- Volunteers
- 24 people
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Portal Hypertension, Cirrhosis
MRI to Assess the Effect of Non-selective Beta-blocker in Patients With Cirrhosis
Background: Standardization and new therapeutic treatments of variceal bleeding has significantly reduced the mortality the last 25 years, but there is still a high 6-week mortality around 15-20% and 1-year mortality of about…
- Conditions
- Portal Hypertension, Cirrhosis, Esophageal Varices, Gastric Varices Bleeding
- Trial name
- NCT03438916
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Hvidovre University Hospital
Cirrhosis, Liver
Improving Pain Management and Opioid Safety for Patients With Cirrhosis
This project aims to test a behavioral intervention in patients with liver cirrhosis and chronic pain and teach self pain-management skills.
- Trial name
- NCT05128578
- Testing
- Liver Education About Pain (LEAP), Usual Care
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Liver Cirrhosis
Safety Study of Autologous Stem Cell in Liver Cirrhosis
It is a fase I/II clinical study to evaluate feasibility, safety and kinetics of cellular therapy with bone marrow-derived mononuclear cells (ABMMC) in patients with liver cirrhosis.
- Trial name
- NCT00382278
- Testing
- Autologous bone marrow-derived mononuclear cells infusion
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Carcinoma, Hepatocellular, Hepatitis C Virus Infection, Response to Therapy of
Possible Differences in HCC Course Depending on DAA Treatment
BACKGROUND It is estimated that around 71 milion people live with chronic hepatitis C virus (HCV) infection. This may lead to the development of liver cirrhosis and hepatocellular carcinoma (HCC).
- Conditions
- Carcinoma, Hepatocellular, Hepatitis C Virus Infection, Response to Therapy of, Drug Effect, Drug Side Effect
- Trial name
- NCT05376943
- Testing
- Direct Acting Antivirals
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
Cirrhosis
Vitamin E Supplement in Patients With Cirrhosis and Acanthocytosis
Acanthocytes, also termed spur cell, are large erythrocytes covered with spike-like projections which are associated with severe hemolytic anemia. In advanced cirrhosis, acanthocytes may account for 20 to 30% of red blood cells.
- Trial name
- NCT01463735
- Testing
- Vitamin E supplement (tocofersolan)
- Where
- Switzerland
- Volunteers
- 27 people
- Sponsor
- University Hospital, Geneva
Chronic Liver Disease and Cirrhosis
Immunological Measurement of Aspartate/Alanine Aminotransferase
Previous reports have suggested that ALT-immunoglobulin complex was increased according to the severity of the liver disease, and high concentration of mAST and this might indicate a severely damaged liver.
- Trial name
- NCT03562585
- Testing
- with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies
- Volunteers
- 219 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Hepatitis B / Liver Space-occupying Lesions / Patients After Ablation
Radiomics for Diagnosing Liver Diseases and Evaluating Progression
Liver diseases are worldwide problems. liver fibrosis and hepatocellular carcinoma are mostly concerned by clinicians. Radiomcis can improve diagnosis accuracy and evaluate disease progression.
- Trial name
- NCT03221049
- Testing
- radiomics
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Cirrhoses, Liver
Allopurinol and Pathogenesis of Cirrhosis
Hepatic decompensation is a common healthcare issue . This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.
- Trial name
- NCT07033533
- Testing
- Allopurinol Tablet
- Where
- Egypt
- Volunteers
- 110 people
- Sponsor
- Tanta University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.